Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer (original) (raw)

Oncogene volume 15, pages 3059–3065 (1997)Cite this article

Abstract

Progression of prostate cancer from an androgen sensitive to androgen insensitive tumor has previously been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer. This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform. We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors. We analysed three well characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice. One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth. Using an RT – PCR based assay, we demonstrated that progressive loss of the FGF-R2(111b) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 50 print issues and online access

$259.00 per year

only $5.18 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Department of Molecular Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA
    Russ P Carstens, James V Eaton & Mariano A Garcia-Blanco
  2. Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA
    Russ P Carstens
  3. Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Russ P Carstens & Mariano A Garcia-Blanco
  4. Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    James V Eaton & Philip J Walther
  5. Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Hannah R Krigman & Philip J Walther
  6. Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Philip J Walther & Mariano A Garcia-Blanco

Authors

  1. Russ P Carstens
    You can also search for this author inPubMed Google Scholar
  2. James V Eaton
    You can also search for this author inPubMed Google Scholar
  3. Hannah R Krigman
    You can also search for this author inPubMed Google Scholar
  4. Philip J Walther
    You can also search for this author inPubMed Google Scholar
  5. Mariano A Garcia-Blanco
    You can also search for this author inPubMed Google Scholar

Rights and permissions

About this article

Cite this article

Carstens, R., Eaton, J., Krigman, H. et al. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.Oncogene 15, 3059–3065 (1997). https://doi.org/10.1038/sj.onc.1201498

Download citation

Keywords